A population based dynamic approach for estimating the cost effectiveness of screening for Chlamydia trachomatis

With great interest, we have read the recent paper in STI on cost effectiveness for Chlamydia trachomatis screening by Honey et al .1 We concur with their conclusion that more data derived from clinical trials are needed for policy making, particularly when considering the evidence on the subsequent risk of pelvic inflammatory disease (PID) in women who test positive for Chlamydia trachomatis . Our paper2 was included and discussed in this review. As our approach was rather complex, we note that some parts of our design and results may have been misinterpreted. Honey et al note that our study was focused on screening both men and women in general practice with an age range for …